Mocht u de informatie op kanker-actueel waarderen dan wilt u misschien ons ondersteunen met een donatie. We zijn en blijven een ANBI organisatie, ook in 2019 dus uw donatie is in principe aftrekbaar voor de belastingen. Ook kunt u korting krijgen bij verschillende bedrijven op voedingssupplementen.

Zie ook in gerelateerde artikelen voor meer informatie over cannabis - marihuana

23 maart 2019: lees ook dit artikel: 

https://kanker-actueel.nl/medicinale-wiet-cannabis-marihuana-vermindert-pijnklachten-en-laat-amerikaanse-werknemers-ouder-dan-50-jaar-langer-werken-na-legalisering-van-de-cannabis-blijkt-uit-10-jarig-onderzoek.html

23 maart 2019: Bron: the Lancet, de Volkskrant en mediwietwebsite

Uit nieuw wetenschappelijk onderzoek blijkt dat mensen die cannabis - marihuana gebruiken met hoge doses THC een groter risico op psychoses lopen op latere leeftijd. Dit blijkt uit een publicatie van dit onderzoek in The lancet van wetenschappers uit verschillende landen waaronder Nederland. Zo zou de stad Amsterdam een halvering van psychotische aandoeningen veroorzaakt door cannabis kunnen halveren door het THC gehalte minder hoog te maken, van 37,9 jaarlijkse gevallen naar 18,8 jaarlijkse gevallen per 100.000 inwoners

Ik heb er zelf te weinig verstand van om hier echt goed onderbouwd commentaar op te geven maar hier achtereenvolgens een artikel uit de Volkskrant , The Lancet zelf en het commentaar op deze studie op mediwiet.nl zodat u zelf uw conclusies kunt trekken.

De Volkskrant schrijft in dit artikel: 

Wetenschappelijke studie laat zien: hoe sterker de wiet, des te groter de kans op psychose

Cannabisgebruik leidt tot een grotere kans op psychoses, met name wanneer het THC-gehalte van cannabis hoog is. THC ofwel tetrahydrocannabinol is de stof die voor een high gevoel zorgt. 

Dat schrijven wetenschappers onder aanvoering van de Londense psychiater Marta Di Forti deze week in het medische tijdschrift The Lancet Psychiatry. Als sterke cannabis niet meer verkrijgbaar zou zijn in Amsterdamse coffeeshops, zou het aantal psychoses kunnen halveren, schatten ze, van 37,9 naar 18,8 jaarlijkse gevallen per 100.000 inwoners.

Het originele studierapport uit The Lancet: 

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study is gratis te lezen of te downloaden. Abstract staat onderaan dit artikel

The EU-GEI incidence study reported an eight-times variation in the incidence rates of psychotic disorder adjusted for age, gender, and ethnic minority status across the study sites.

We found a correlation between the adjusted incidence rates for psychotic disorder in our 11 sites and the prevalence of daily cannabis use in controls (r=0·8; p=0·0109). Sites where daily use was common such as London (26 [11·7%] of 223 controls) and Amsterdam (13 [13·0%] of 100 controls) had among the highest adjusted incidence rates (45·7 cases per 100 000 person-years in London and 37·9 per 100 000 person-years in Amsterdam). This differed from sites such as Bologna where daily use was less frequent (three [4·6%] of 65 controls) and the adjusted incidence rate was half that of London (21·0 cases per 100 000 per person years; figure 3).

Figure thumbnail gr3
Figure 3Adjusted incidence rates for all psychosis for the 11 sites plotted against the prevalence of daily use in the population controls (A) and prevalence of use of high-potency cannabis in the population controls (B)

Mediwiet schrijft in dit artikel: Lancet-onderzoek: Sterkere wiet verhoogt kans op psychose dat zij vraagtekens hebben bij de opzet van het onderzoek:

3 x meer risico

Onder de deelnemers waren 900 patiënten die zich voor het eerst meldden bij een zorginstantie vanwege psychotische klachten. Tijdens het onderzoek bleek dat deze groep veel vaker wiet gebruikte dan de controlegroep met daarin 1200 mensen zonder psychoses.

In de groep met 900 personen gebruikte 30 procent dagelijks cannabis tegenover een kleine 7 procent in de controlegroep. Ook zagen de wetenschappers dat de patiënten twee keer vaker sterkere wiet gebruikten dan de controlegroep. Dat is volgens de studie wiet met een THC-gehalte van 10 procent of meer.

Alles bij elkaar berekenden de onderzoekers dat dagelijks cannabisgebruik het risico op psychoses met drie keer vergroot. Bij sterkere cannabis, met 10 procent THC of meer, is dat zelfs vijf keer. Ook gaven ze aan dat het risico in Nederland mogelijk nog groter is, omdat hele hoge THC-percentages hier eerder regel zijn dan uitzondering.>>>>>>>lees verder het commentaar op mediwietwebsite.nl

Hiuer het abstract van de studie uit The lancet:

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

  • Marta Di Forti
    Correspondence
    Correspondence to: Dr Marta Di Forti, Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
    Affiliations
    Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London, UK

    National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, UK

    South London and Maudsley NHS Mental Health Foundation Trust, London, UK
    Search for articles by this author
    Show all authors
  • Author Footnotes
    † Collaborators listed in the appendix
Open AccessPublished:March 19, 2019DOI:https://doi.org/10.1016/S2215-0366(19)30048-3

Summary

Background

Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder.

Methods

We included patients aged 18–64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ9-tetrahydrocannabinol (THC) in the different types of cannabis available across the sites, we divided the types of cannabis used by participants into two categories: low potency (THC <10%) and high potency (THC ≥10%). Assuming causality, we calculated the population attributable fractions (PAFs) for the patterns of cannabis use associated with the highest odds of psychosis and the correlation between such patterns and the incidence rates for psychotic disorder across the study sites.

Findings

Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio 3·2, 95% CI 2·2–4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5–6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0–16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2–40·0) in London and 50·3% (27·4–66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109).

Interpretation

Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health.

Funding source

Medical Research Council, the European Community's Seventh Framework Program grant, São Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.

References

    • Grucza RA
    • Agrawal A
    • Krauss MJ
    • Cavazos-Rehg PA
    • Bierut LJ
    Recent trends in the prevalence of marijuana use and associated disorders in the united states.
    JAMA Psychiatry. 2016; 73: 300-301
    • Hall W
    • Lynskey M
    Evaluating the public health impacts of legalizing recreational cannabis use in the United States.
    Addiction. 2016; 111: 1764-1773
    • Wilkinson ST
    • Yarnell S
    • Radhakrishnan R
    • Ball SA
    • D'Souza DC
    Marijuana legalization: impact on physicians and public health.
    Annu Rev Med. 2016; 67: 453-466
    • Gage SH
    • Hickman M
    • Zammit S
    Association between cannabis and psychosis: epidemiologic evidence.
    Biol Psychiatry. 2016; 79: 549-556
    • Mustonen A
    • Niemelä S
    • Nordström T
    • et al.
    Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis.
    Br J Psychiatry. 2018; 212: 227-233
    • Murray RM
    • Englund A
    • Abi-Dargham A
    • et al.
    Cannabis-associated psychosis: neural substrate and clinical impact.
    Neuropharmacology. 2017; 124: 89-104
    • Marconi A
    • Di Forti M
    • Lewis CM
    • Murray RM
    • Vassos E
    Meta-analysis of the association between the level of cannabis use and risk of psychosis.
    Schizophr Bull. 2016; 42: 1262-1269
    • Ksir C
    • Hart CL
    Cannabis and psychosis: a critical overview of the relationship.
    Curr Psychiatry Rep. 2016; 18: 12
    • Hill M
    Perspective: be clear about the real risks.
    Nature. 2015; 525: S14
    • Boydell J
    • van Os J
    • Caspi A
    • et al.
    Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999.
    Psychol Med. 2006; 36: 1441-1446
    • McGrath J
    • Saha S
    • Welham J
    • El Saadi O
    • MacCauley C
    • Chant D
    A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology.
    BMC Med. 2004; 2: 13
    • Jongsma HE
    • Gayer-Anderson C
    • Lasalvia A
    • et al.
    Treated incidence of psychotic disorders in the multinational EU-GEI study.
    JAMA Psychiatry. 2018; 75: 36-46
    • McGuffin P
    • Farmer A
    • Harvey I
    A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the opcrit system.
    Arch Gen Psychiatry. 1991; 48: 764-770
    • Mallett R
    • Leff J
    • Bhugra D
    • Pang D
    • Zhao JH
    Social environment, ethnicity and schizophrenia: a case-control study.
    Soc Psychiatry Psychiatr Epidemiol. 2002; 37: 329-335
    • Di Forti M
    • Morgan C
    • Dazzan P
    • et al.
    High-potency cannabis and the risk of psychosis.
    Br J Psychiatry. 2009; 195: 488-491
    • Casadio P
    • Fernandes C
    • Murray RM
    • Di Forti M
    Cannabis use in young people: the risk for schizophrenia.
    Neurosci Biobehav Rev. 2011; 35: 1779-1787
    • European Monitoring Centre for Drugs and Drug Addiction
    European drug report 2016: trends and developments. Publications Office of the European Union, Luxembourg; 2016
    • European Monitoring Centre for Drugs and Drug Addiction
    • Spanish Ministry of Health and Consumer Affairs
    Spain national report (2011 data) to the EMCDDA 2012. Government Delegation for National Plan on Drugs, Madrid; 2012
    • Niesink R
    • Rigter S
    THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops (2012–2013). AF1221. Trimbos-instituut, Utrecht; 2013
    • Brisacier A-C
    • Cadet-Taïrou A
    • Díaz Gómez C
    • et al.
    Drogues, chiffres clés. Observatoire Français des Drogues et des Toxicomanies, Paris; 2015
    • Zamengo L
    • Frison G
    • Bettin C
    • Sciarrone R
    Cannabis potency in the Venice area (Italy): update 2013.
    Drug Test Anal. 2015; 7: 255-258
    • Niesink RJM
    • Rigter S
    • Koeter MW
    • Brunt TM
    Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15.
    Addiction. 2015; 110: 1941-1950
    • de Oliveira GL
    • Voloch MH
    • Sztulman GB
    • Neto ON
    • Yonamine M
    Cannabinoid contents in cannabis products seized in São Paulo, Brazil, 2006–2007.
    Forensic Toxicol. 2008; 26: 31-35
    • Potter DJ
    • Clark P
    • Brown MB
    Potency of Δ9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology.
    J Forensic Sci. 2008; 53: 90-94
    • Hardwick S
    • King S
    Home Office cannabis potency study 2008. Home Office Scientific Development Branch, London; 2008
    • Taylor M
    • Sullivan J
    • Ring SM
    • Macleod J
    • Hickman M
    Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people.
    Addiction. 2016; 112: 477-485
    • Orsini N
    • Bellocco R
    • Bottai M
    • Wolk A
    • Greenland S
    A tool for deterministic and probabilistic sensitivity analysis of epidemiologic studies.
    Stata J. 2008; 8: 29-48
    • Di Forti M
    • Marconi A
    • Carra E
    • et al.
    Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.
    Lancet Psychiatry. 2015; 2: 233-238
    • Potter DJ
    • Hammond K
    • Tuffnell S
    • Walker C
    • Forti MD
    Potency of Δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology.
    Drug Test Anal. 2018; 10: 628-635
    • Freeman TP
    • van der Pol P
    • Kuijpers W
    • et al.
    Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands.
    Psychol Med. 2018; 48: 2346-2352
    • Murray RM
    • Quigley H
    • Quattrone D
    • Englund A
    • Di Forti M
    Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.
    World Psychiatry. 2016; 15: 195-204
    • Freeman TP
    • Morgan CJA
    • Hindocha C
    • Schafer G
    • Das RK
    • Curran HV
    Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?.
    Addiction. 2014; 109: 1686-1694
    • Curran HV
    • Hindocha C
    • Morgan CJ
    • Shaban N
    • Das RK
    • Freeman TP
    Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?.
    Psychol Med. 2018; (published online Sept 4. DOI:10.1017/S003329171800226X.)
    • Englund A
    • Freeman TP
    • Murray RM
    • McGuire P
    Can we make cannabis safer?.
    Lancet Psychiatry. 2017; 4: 643-648
    • Mokrysz C
    • Freeman TP
    • Korkki S
    • Griffiths K
    • Curran HV
    Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males.
    Transl Psychiatry. 2016; 6: e961
    • Marshall M
    • Lewis S
    • Lockwood A
    • Drake R
    • Jones P
    • Croudace T
    Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review.
    Arch Gen Psychiatry. 2005; 62: 975-983

Plaats een reactie ...

Reageer op "Cannabis gebruik met hoge THC gehaltes leidt tot meer psychoses op latere leeftijd aldus nieuw wetenschappelijk onderzoek"


Gerelateerde artikelen
 

Gerelateerde artikelen

Medicinale wiet (cannabis >> Cannabis gebruik met hoge >> Recreatief gebruik van marihuana >> 80 procent van amerikaanse >> DE WATERKOKER VAN MIJN TANTE >> Waar kan ik marihuana of >> Cannabisstofjes CBD en THC >> Cannabis olie - wietolie moet >> Cannabis - marihuana toegevoegd >> Cannabis - THC CBD extract >>